Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | CHKA | P35790 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | GAA | P10253 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | GFER | P55789 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | NCF1 | P14598 | 1/20 | 0.57 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28758087 | 0.91 | KDM4E (0.61) | ALDH1A1CHKAKDM4EGAAMAPT | |
| SCHEMBL24478669 | 0.88 | ALDH1A1 (0.52) | ALDH1A1CHKAKDM4EGAAMAPT | |
| SCHEMBL8353735 | 0.84 | CHKA (0.57) | ALDH1A1CHKAKDM4EGAAMAPT | |
| SCHEMBL12128002 | 0.83 | KDM4E (0.63) | KDM4EMAPTRAB9ANPC1MAPK1 | |
| SCHEMBL23655782 | 0.83 | ADRB1 (0.53) | ALDH1A1KDM4EGAAMAPTGFER | |
| SCHEMBL23543151 | 0.83 | L3MBTL3 (0.55) | ALDH1A1KDM4EMAPTKMT2ARAB9A | |
| SCHEMBL19718448 | 0.83 | KMT2A (0.55) | ALDH1A1KDM4EMAPTKMT2ARAB9A | |
| SCHEMBL12313402 | 0.83 | POLB (0.62) | ALDH1A1KDM4EGAAMAPTGFER | |
| SCHEMBL24715763 | 0.83 | KDM4E (0.57) | ALDH1A1CHKAKDM4EGAAMAPT | |
| SCHEMBL2056142 | 0.83 | KDM4E (0.57) | ALDH1A1CHKAKDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024039210-A1 | COMPOUNDS FOR INHIBITING OR DECOMPOSING CDK2 AND/OR CDK9, AND MEDICINAL USES THEREOF | 한국화학연구원 | 2024-02-22 | — | — | WO | disclosed |
| EP-3647311-B1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-11771775-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11702473-B2 | Site-specific antibody-drug conjugates | MEDIMMUNE LIMITED (GB) | 2023-07-18 | — | — | US | disclosed |
| US-11690918-B2 | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-07-04 | — | — | US | disclosed |
| US-11649250-B2 | Pyrrolobenzodiazepine conjugates | MEDIMMUNE LIMITED (GB) | 2023-05-16 | — | — | US | disclosed |
| US-11548890-B1 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11524969-B2 | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents | MEDIMMUNE LIMITED (GB) | 2022-12-13 | — | — | US | disclosed |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-07-26 | — | — | US | disclosed |
| WO-2007053452-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-7173004-B2 | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| WO-2006077424-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077428-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077414-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077425-A1 | COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006074924-A1 | 3,4,(5)-SUBSTITUTED TETRAHVDROPYRIDINES | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
| WO-2005012256-A1 | 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| WO-2003020278-A1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548890-B1 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | ALDH1A1 4740/4885CHKA 209/4885KDM4E 3143/4885 |
| US-11690918-B2 | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | CD22, CD2, CD2BP2 | ALDH1A1 778/4885CHKA 2853/4885KDM4E 1572/4885 |
| US-11524969-B2 | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents | PBRM1, HDAC6, NPM1 | ALDH1A1 1297/4885CHKA 2567/4885KDM4E 1557/4885 |
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | ALDH1A1 4351/4885CHKA 870/4885KDM4E 983/4885 |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAPKAPK5, MAPKAPK3 | ALDH1A1 2911/4885CHKA 1474/4885KDM4E 1843/4885 |
| US-11649250-B2 | Pyrrolobenzodiazepine conjugates | CD79B, GABRG2, GABRA1 | ALDH1A1 169/4885CHKA 1683/4885KDM4E 1880/4885 |
| US-11771775-B2 | Pyrrolobenzodiazepine-antibody conjugates | CD79B, BCL6B, BCL6 | ALDH1A1 3769/4885CHKA 3295/4885KDM4E 1391/4885 |
| US-11702473-B2 | Site-specific antibody-drug conjugates | SBDS, DCTD, DRD1 | ALDH1A1 442/4885CHKA 1809/4885KDM4E 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.